Bridgepoint Development Capital has bought Phlexglobal, a provider of document management solutions and support services to the global clinical research market, from Inflexion for £42 million ($72 million). Lloyds Bank Commercial Banking provided senior debt and working capital facilities. Phlexglobal specializes in Trial Master File software and services; required by law, TMF is a collection of all essential documents created during a clinical trial that demonstrates compliance with regulatory standards. For the year to December 2013, Phlexglobal reported revenue and EBITDA of £15.3 million ($26.1 million) and £4.5 million ($7.7 million) respectively. Inflexion had bought it in 2011.